{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-007402","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2022-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.622258+00:00","generated_at":"2026-06-26T00:22:51.042464+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Acadia Q1 NUPLAZID sales $115.5M (+8% YoY); net loss widens to $113.1M on $60M Stoke payment","bullets":["Q1 NUPLAZID net sales $115.5M (+8% vs $106.6M Q1 2021); net loss $113.1M ($0.70/sh) vs $66.4M loss in prior year.","R&D expense surged to $128.9M from $57.0M, driven by $60M upfront payment to Stoke Therapeutics under license deal.","Cash and investments $446.0M at March 31, 2022, down from $520.7M at Dec 31, 2021.","FY2022 NUPLAZID net sales guidance reiterated at $510-$560M; FDA AdComm for pimavanserin in ADP set for June 17, 2022.","Trofinetide NDA for Rett syndrome on track for mid-2022; Parag Meswani and Holly Valdiviez joined as senior commercial leads."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-007402","json":"https://secwatch.observer/filing/0000950170-22-007402.json","markdown":"https://secwatch.observer/filing/0000950170-22-007402.md","text":"https://secwatch.observer/filing/0000950170-22-007402.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000095017022007402/0000950170-22-007402-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000095017022007402/acad-20220504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:22:51.042464+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}